Union Therapeutics strikes million-dollar deal with Chinese partner

The drug orismilast, intended to treat different dermatological disorders, and which Union Therapeutics bought from Leo Pharma last year, is now the basis of an agreement worth millions of US dollars for the Danish biotech company.
Photo: Union Therapeutics / PR
Photo: Union Therapeutics / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

When the drug orismilast comes to China, the biotech company Union Therapeutics, headquartered in Denmark, will collaborate with Innovent Biologics, informs the Danish company in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading